{'fraction_non_alphanumeric': 0.02745664739884393, 'fraction_numerical': 0.023121387283236993, 'mean_word_length': 5.382488479262673, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 6007: Identification of drivers of soft tissue sarcoma metastasis


 Soft tissue sarcomas are a rare and heterogeneous group of tumors with a 65% five-year survival rate despite aggressive treatment with surgery, radiation, and chemotherapy. Even with intensive multimodality treatment, many patients will develop incurable metastatic disease, providing evidence that our current therapies are ineffective and new treatments are desperately needed. Pre-clinical models to study metastasis of human soft tissue sarcomas are limited. We have developed a system that allows for the formation of distinct soft tissue sarcoma subtypes from mesenchymal stem cells that have been depleted of p53 and Rb1 using CRISPR. Injection of these cells intramuscularly results in metastasis to the lung. Using this novel model system, we have performed a genetic screen to identify pathways and specific drivers of sarcoma metastasis. This pre-clinical in vivo model system will allow for the identification of putative therapeutic targets to prevent the development of lethal metastatic growth.
 Citation Format: Janai R. Carr-Ascher, Maria Munoz. Identification of drivers of soft tissue sarcoma metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6007.